Bryan Hanson

Bryan Hanson leads Zimmer Biomet as Chairman and CEO, overseeing the world's largest pure-play orthopedic medical device company. Zimmer Biomet produces joint replacement implants for hips, knees, and shoulders, spine implants, dental implants, and the ROSA (Robotic Surgical Assistant) platform for robotic-assisted joint replacement surgery. The company's implants restore mobility to millions of patients annually suffering from osteoarthritis and other degenerative conditions. The orthopedic implant market benefits from powerful demographic tailwinds: aging populations globally are driving steadily increasing demand for joint replacement procedures. The baby boomer generation in the U.S. is entering peak joint replacement years. Additionally, younger and more active patients are increasingly opting for joint replacement rather than living with chronic pain, expanding the addressable market. Zimmer Biomet's ROSA robotic surgery platform is a strategic asset: robotic-assisted surgery improves surgical precision and outcomes, and hospitals that invest in a ROSA system tend to purchase Zimmer Biomet implants — creating a "razor and blade" dynamic. Key stock drivers include hip and knee procedure volume growth, ROSA robotic platform adoption, market share in large joint reconstruction, spine and dental segment performance, competition with Stryker, Johnson & Johnson DePuy, and Smith+Nephew, pricing pressure from hospital group purchasing organizations, R&D pipeline and new product launches, and global procedure volume recovery and growth.